Home › Research › Treatments
Efficacy of naftidrofuryl in patients with vascular or mixed dementia: results of a multicenter, double-blind trial
Emeriau JP, Lehert P, Mosnier M.. Clinical therapeutics, 2000-07-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Background Dementia is a cerebral disorder resulting in a progressive deterioration of intellectual function that compromises the patient's ability to function. The diagnostic criteria for dementia are primarily clinical and are based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. The Hachinski score and computed tomography of the brain help distinguish between degenerative and vascular dementias. Objective This study examined the efficacy of naftidrofuryl in patients with vascular or mixed dementia. Methods This multicenter, randomized, double-blind study compared naftidrofuryl 600 mg/d with placebo for 1 year in patients with vascular or mixed dementia. A preliminary 2-month washout period allowed selection of patients who were compliant with treatment. The end point was change in the scores on the Alzheimer Disease Assessment Scale cognitive subscale and the Mini-Mental State Examination. Results Eighty-four patients were assessable on an intent-to-treat basis, and 74 were assessable for the per-protocol analysis (on-treatment). Statistically significant improvements in cognitive and global function were observed in patients receiving naftidrofuryl. Naftidrofuryl was well tolerated, and produced no clinically significant abnormalities in laboratory test results. Conclusion The results of this study suggest that naftidrofuryl is effective and well tolerated in treating the symptoms of vascular and mixed dementia.
What this study adds
Evidence grade: High
This is a trial. In this one-year trial of 84 patients with vascular or mixed dementia, naftidrofuryl 600 mg/d produced statistically significant improvements in cognitive and global function compared with placebo. The authors concluded that naftidrofuryl is effective and well tolerated for treating the symptoms of these dementias.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Emeriau, J. P., Lehert, P., & Mosnier, M. (2000). Efficacy of naftidrofuryl in patients with vascular or mixed dementia: results of a multicenter, double-blind trial. Clinical therapeutics. https://doi.org/10.1016/s0149-2918(00)80056-9
Vancouver
Emeriau JP, Lehert P, Mosnier M. Efficacy of naftidrofuryl in patients with vascular or mixed dementia: results of a multicenter, double-blind trial. Clinical therapeutics. 2000. doi:10.1016/s0149-2918(00)80056-9. PMID: 10945510.
BibTeX
@article{emeriau2000-10945510,
author = {Emeriau, J. P. and Lehert, P. and Mosnier, M.},
title = {{Efficacy of naftidrofuryl in patients with vascular or mixed dementia: results of a multicenter, double-blind trial}},
journal = {Clinical therapeutics},
year = {2000},
doi = {10.1016/s0149-2918(00)80056-9},
pmid = {10945510},
url = {https://doi.org/10.1016/s0149-2918(00)80056-9}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Results Eighty-four patients were assessable on an intent-to-treat basis, and 74 were assessable for the per-protocol analysis (on-treatment).
- Statistically significant improvements in cognitive and global function were observed in patients receiving naftidrofuryl.
- Naftidrofuryl was well tolerated, and produced no clinically significant abnormalities in laboratory test results.
- Conclusion The results of this study suggest that naftidrofuryl is effective and well tolerated in treating the symptoms of vascular and mixed dementia.
Why it matters
In this one-year trial of 84 patients with vascular or mixed dementia, naftidrofuryl 600 mg/d produced statistically significant improvements in cognitive and global function compared with placebo. The authors concluded that naftidrofuryl is effective and well tolerated for treating the symptoms of these dementias.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthHigh
How this study scored 52/100
Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for sample size and effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Clinical therapeutics) |
| Journal's citation record | 2 / 4 | Clinical Therapeutics: journal h-index 173 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2000 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (pubmed indexes it as a clinical or observational study) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 3 / 7 | Cited 20 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.7 citations a year over 28 year(s) since 2000 |
| Impact for its field and year | 2 / 6 | Cited 1.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Michel Mosnier: h-index 6 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | University of Mons: institution h-index 408 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | PubMed indexes it as a multicentre study |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 10945510) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 52 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.